![OREXO AB [CBOE]](/medias/logo_company/7Z3Pv9WAHim7j4u.png "OREXO AB [CBOE]"){kind=logo}
OREXO AB [CBOE] news, videos and press releases
For more news please use our advanced search feature.
OREXO AB [CBOE] - More news...
OREXO AB [CBOE] - More news...
- Report from Orexo AB's annual general meeting, 26 April 2024
- Report from Orexo AB's annual general meeting, 26 April 2024
- Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US
- Orexo announces that the condition for early redemption of its existing bonds has been fulfilled
- Orexo announces that the condition for early redemption of its existing bonds has been fulfilled
- Orexo publishes the Annual and Sustainability Report for 2023
- Orexo publishes the Annual and Sustainability Report for 2023
- Correction: Notice of Annual General Meeting of Orexo
- Correction: Notice of Annual General Meeting of Orexo
- Notice of Annual General Meeting of Orexo
- Orexo successfully issues senior secured callable floating rate social bonds of SEK 500 m and announces results of the tender offer for its existing bonds
- Orexo successfully issues senior secured callable floating rate social bonds of SEK 500 m and announces results of the tender offer for its existing bonds
- Orexo strengthens its sustainability work by establishing a social financing framework
- Orexo contemplates issuance of senior secured callable floating rate social bonds and announces a conditional tender offer for its existing bonds
- Orexo strengthens its sustainability work by establishing a social financing framework
- Orexo contemplates issuance of senior secured callable floating rate social bonds and announces a conditional tender offer for its existing bonds
- Orexo and Sobi agree to advance feasibility study with AmorphOX
- Orexo Interim Report Q4 2023, incl. Full Year Report
- Orexo Interim Report Q4 2023, incl. Full Year Report
- Orexo's OX640 development results to be presented at the 2024 AAAAI Annual Meeting in Washington, DC
- Orexo announces FDA acceptance of New Drug Application filing for OX124, a high-dose rescue medication for opioid overdose
- Orexo Q3 2023 Interim Report
- Orexo Q3 2023 Interim Report
- Orexo announces changes in the company´s Board of Directors
- Orexo´s Nomination Committee for the Annual General Meeting 2024
- Orexo´s Nomination Committee for the Annual General Meeting 2024
- Report from Orexo´s extraordinary general meeting
- Report from Orexo´s extraordinary general meeting
- Orexo announces data from the MODIA® study evaluating impact on use of illicit opioids
- Notice of Extraordinary General Meeting in Orexo AB (publ)
